Amgen's experimental jab causes 20 per cent weight loss in early results
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
biopharma-reporter7h
Amgen announces positive Phase 2 results for its GLP-1-GIP weight loss drug
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
PipelineReview.com10h
Amgen announces robust weight loss with maritide in people living with obesity or overweight at 52 weeks in a phase 2 study
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
AMGN Stock Down Despite Strong Data From Obesity Drug Study
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
devdiscourse22h
Health News Highlights: Thyroid Pill Risks and Pharmaceutical Updates
This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...